Acquired Resistance to Antituberculosis Drugs

Htin Lin Aung, Wint Wint Nyunt, Yang Fong, Bruce Russell, Gregory M. Cook, Si Thu Aung

Author affiliations: University of Otago, Dunedin, New Zealand (H.L. Aung, B. Russell, G.M. Cook); Ministry of Health and Sports, Yangon, Myanmar (W.W. Nyunt); Massey University, Palmerston North, New Zealand (Y. Fong); Ministry of Health and Sports, Naypyitaw, Myanmar (S.T. Aung)

DOI: https://doi.org/10.3201/eid2411.180465

To the Editor: We read with great interest the article by Loutet et al. on acquired resistance to antituberculosis drugs in low-burden settings, such as England, Wales, and Northern Ireland (1). We believe WGS is even more vital to help direct MDR TB treatment in high-burden settings, to halt the continued spread of TB.

Ethics approval for this study was given by the Ethics Review Committee of Department of Medical Research, Yangon, Myanmar.

This work was supported by the New Zealand Health Research Council (grant number 15/648 and 18/024).

References


Address for correspondence: Htin Lin Aung, Sir Charles Hercus Health Research Fellow, Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, PO Box 56, Dunedin, New Zealand; email: htin.aung@otago.ac.nz